Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)

The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. This is a case series of 45 patients with FLG3 treated with frontline R-CHOP and observed for an extended time interval. The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph node sites more than 4 and presence of B symptoms.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L. Jeffrey Medeiros, Michael J. Overman, Jorge E. Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B. Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S. Neelapu, Luis Source Type: research